Nicole Giske

Nicole Giske

Oregon Health & Science University, Portland, Oregon, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Thomas Lee SuttonThomas Lee Sutton
Thomas Lee Sutton
RPResident Kamalesh Patel
Resident Kamalesh Patel
AAAshley Anderson
Ashley Anderson
SBStephen G. Bowden
Stephen G. Bowden
Riley M WhalenRiley M Whalen
Riley M Whalen
MWMelissa H. Wong
Melissa H. Wong
Cancer remains a significant cause of mortality in developed countries, due in part to difficulties in early detection, understanding disease biology, and assessing treatment response. If effectively harnessed, circulating biomarkers promise to fulfill these needs through non-invasive “liquid” biopsy. While tumors disseminate genetic material and cellular debris into circulation, identifying clinically relevant information from these analytes has proven difficult. In contrast, cell-based circulating biomarkers have multiple advantages, including a source for tumor DNA and protein, and as a cellular reflection of the evolving tumor. While circulating tumor cells (CTCs) have dominated the circulating cell biomarker field, their clinical utility beyond that of prognostication has remained elusive, due to their rarity. Recently, two novel populations of circulating tumor-immune hybrid cells in cancer have been characterized: cancer-associated macrophage-like cells (CAMLs) and circulating hybrid cells (CHCs). CAMLs are macrophage-like cells containing phagocytosed tumor material, while CHCs can result from cell fusion between cancer and immune cells and play a role in the metastatic cascade. Both are detected in higher numbers than CTCs in peripheral blood and demonstrate utility in prognostication and assessing treatment response. Additionally, both cell populations are heterogeneous in their genetic, transcriptomic, and proteomic signatures, and thus have the potential to inform on heterogeneity within tumors. Herein, we review the advances in this exciting field.

24 November 2023
Verified
Book Chapter
Closed access
PDF file
RPRanish K. Patel
Ranish K. Patel
MPMichael Parappilly
Michael Parappilly
SRShahrose Rahman
Shahrose Rahman
ISIssac R. Schwantes
Issac R. Schwantes
MSMarisa Sewell
Marisa Sewell
MWMelissa H. Wong
Melissa H. Wong

22 May 2026
Verified
Book Chapter
Closed access
KFKathryn L. Fowler
Kathryn L. Fowler
AAAshley Anderson
Ashley Anderson
TETaelor J. Ekstrom
Taelor J. Ekstrom
NGNicole Giske
Nicole Giske
AMAbigail Moore
Abigail Moore
MWMelissa H. Wong
Melissa H. Wong